Search

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Jun 11 2016 Posted in Press releases

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic leukaemia patients

Jun 10 2016 Posted in Press releases

Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.

Acute Lymphocytic Leukemia: impressive results with the monoclonal antibody blinatumomab

Jun 15 2012 Posted in Press releases

The Phase 2 dose-ranging study MT103-206 evaluated the efficacy, safety and tolerability of blinatumomab in adult patients with B-precursor Acute Lymphoblastic Leukemia who had relapsed following treatment with standard front-line chemotherapy or allogeneic stem cell transplant.

Can Eltrombopag help children with ITP say goodbye to bleeding?

Jun 13 2014 Posted in Press releases

Immune thrombocytopenia (ITP) is a rare disease in children, affecting 5 in 100,000. Most children get better quickly without intervention but up to 30% will still have disease at 12 months.

Abstract submission & Awards

Abstract and Case Report submission is now closed. Abstract awardsIntroduced in 2021 and after 3 editions, we are excited to announce the 4th Emerging Investigators EHA-EBMT Joint Fellowship Awards in the Field of Cell Therapy and Immunotherapy 2024.